The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO 2019 | IMpower133: atezolizumab, carboplatin plus etoposide for SCLC

Name: IMpower133: atezolizumab, carboplatin plus etoposide for SCLC
Uploaded: 2019-09-30T00:00:00Z
Duration: 1 min 50 s
Description: Martin Reck, MD, PhD, German Center of Lung Research, Grosshansdorf, Germany, discusses the IMpower133 (NCT02763579) trial updated overall survival (OS) analysis of first-line atezolizumab plus carboplatin plus etoposide in extensive-stage small-cell lung cancer SCLC. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Martin Reck • 30 Sep 2019

ESMO 2019

Lung Cancer Small Cell Lung Cancer Atezolizumab Carboplatin Etoposide

IMpower133

Martin Reck, MD, PhD, German Center of Lung Research, Grosshansdorf, Germany, discusses the IMpower133 (NCT02763579) trial updated overall survival (OS) analysis of first-line atezolizumab plus carboplatin plus etoposide in extensive-stage small-cell lung cancer SCLC. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.